A recent phase III trial published in JCO describes the NVALT-11/DLCRG-02 study, evaluating PCI vs observation in patients with stage III NSCLC s/p concurrent/sequential chemoradiation. The study met its primary endpoint of significant increase in time to development of symptomatic brain mets in patients who received PCI, but did not show any improvement in OS.